Grifols | GRFS - Operating Profit


Grifols reported EUR320.55M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Alaunos Therapeutics USD -1.19M 148K Sep/2025
Arca Biopharma USD -34.43M 326K Dec/2025
aTyr Pharma USD 24.47M 51.21M Dec/2025
Bio Path USD -488K 4.07M Sep/2025
Brainstorm Cell Therapeutics USD -2.24M 197K Dec/2025
Capricor Therapeutics USD -29.16M 2.87M Dec/2025
Cara Therapeutics USD -5.94M 3.55M Sep/2025
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Grifols EUR 320.55M 91.01M Dec/2025
Immunic USD -25.73M 2.91M Sep/2024
Infinity Pharmaceuticals USD -10.12M 1.39M Jun/2023
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
TherapeuticsMD USD -1.18M 40K Jun/2024